News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ajinomoto and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Release: A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved in Japan



4/18/2007 11:57:43 AM

Tokyo, Apr 18, 2007 (JCN Newswire) - Ajinomoto Co., Inc. ("Ajinomoto", President and CEO: Norio Yamaguchi, Headquarters: Tokyo) and Takeda Pharmaceutical Company Limited ("Takeda", President: Yasuchika Hasegawa, Headquarters: Osaka) are pleased to announce that the Ministry of Health, Labour and Welfare approved today "Actonel(R) 17.5 mg tablets" and "Benet(R) 17.5 mg tablets", a once-weekly formulation of risedronate sodium hydrate (generic name) for the treatment of osteoporosis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES